Cynata Therapeutics requests trading halt

Cynata Therapeutics (ASX:CYP), a company at the forefront of stem cell and regenerative medicine, has announced a trading halt on its securities. This decision is pending the release of results from a Phase 1 clinical trial focused on diabetic foot ulcers. The halt is expected to remain in place until the outcome is released or until regular trading resumes on Friday, 6 December 2024.

Cynata's strategic focus and upcoming developments

Cynata Therapeutics has requested a trading halt pending the announcement of results from its Phase 1 trial on diabetic foot ulcers. The company is known for its proprietary Cymerus™ stem cell technology, which leverages iPSCs and MCAs to create scalable cell therapy solutions. Cynata's clinical pipeline includes trials for various conditions, such as GvHD, osteoarthritis, and renal transplant. The Phase 1 trial for diabetic foot ulcers has completed patient enrolment. Cynata's ongoing commitment to advancing stem cell therapy highlights their potential impact on diverse medical conditions, with anticipated trial results potentially shaping future investor interest and company trajectory.

Executive commentary on trading halt

The trading halt has been requested to ensure the market is fully informed about the outcomes of our clinical trial before trading resumes. We are committed to transparency and providing our investors with timely and accurate information.